Search research articles
Contact Us
Filters
Showing results (101-110 of 721) with videos related to
Page
of 73
Sort By:
Seminars in Nuclear Medicine
|
July 17, 2025
The Value of FAPI PET/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update
Kim M Pabst, Wolfgang P Fendler, Leonie S Jochheim, et al.
Pharmaceuticals (Basel, Switzerland)
|
July 27, 2022
Fully Automated, High-Dose Radiosynthesis of [<sup>18</sup>F]PARPi
Anna Pacelli, Fadi Zarrad, Wolfgang P Fendler, et al.
European Journal of Clinical Investigation
|
May 17, 2023
Prognostic role of early prostate specific antigen changes after [<sup>177</sup> Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: A meta-analysis
Luca Giovanella, Maria Luisa Garo, Marco Cuzzocrea, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
June 11, 2024
Cost-Effectiveness and Budget Impact Analyses of Selective Internal Radiation Therapy versus Atezolizumab Plus Bevacizumab from a German Statutory Health Insurance Perspective
Bjoern Schwander, Katharina Klesper, Siegbert Rossol, et al.
PET Clinics
|
May 10, 2016
Alternative PET Tracers in Musculoskeletal Disease
Akram Al-Ibraheem, Andreas K Buck, Ambros J Beer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 11, 2022
Virtual Biopsy: Just an AI Software or a Medical Procedure?
Jacob M Murray, Bodo Wiegand, Boris Hadaschik, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 22, 2021
2021: the year [<sup>177</sup>Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to "A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands" by Dr. Germo Gericke
Ken Herrmann, Clemens Kratochwil, Wolfgang P Fendler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 1, 2017
<sup>177</sup>Lu-PSMA Radioligand Therapy for Prostate Cancer
Wolfgang P Fendler, Kambiz Rahbar, Ken Herrmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 16, 2017
Comparison of <sup>68</sup>Ga-PSMA-11 and <sup>18</sup>F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence
Jeremie Calais, Wolfgang P Fendler, Ken Herrmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 3, 2017
CXCR4 Ligands: The Next Big Hit?
Annemiek M E Walenkamp, Constantin Lapa, Ken Herrmann, et al.
Page
of 73
Search research articles
Search
Showing results (101-110 of 721) with videos related to
Sort By:
Page
of 73
Seminars in Nuclear Medicine
|
July 17, 2025
The Value of FAPI PET/CT in Cholangiocarcinoma and Pancreatic Cancer: An Update
Kim M Pabst, Wolfgang P Fendler, Leonie S Jochheim, et al.
Pharmaceuticals (Basel, Switzerland)
|
July 27, 2022
Fully Automated, High-Dose Radiosynthesis of [<sup>18</sup>F]PARPi
Anna Pacelli, Fadi Zarrad, Wolfgang P Fendler, et al.
European Journal of Clinical Investigation
|
May 17, 2023
Prognostic role of early prostate specific antigen changes after [<sup>177</sup> Lu]Lu-PSMA radioligand therapy of metastasized prostate cancer: A meta-analysis
Luca Giovanella, Maria Luisa Garo, Marco Cuzzocrea, et al.
Clinicoeconomics and Outcomes Research : CEOR
|
June 11, 2024
Cost-Effectiveness and Budget Impact Analyses of Selective Internal Radiation Therapy versus Atezolizumab Plus Bevacizumab from a German Statutory Health Insurance Perspective
Bjoern Schwander, Katharina Klesper, Siegbert Rossol, et al.
PET Clinics
|
May 10, 2016
Alternative PET Tracers in Musculoskeletal Disease
Akram Al-Ibraheem, Andreas K Buck, Ambros J Beer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 11, 2022
Virtual Biopsy: Just an AI Software or a Medical Procedure?
Jacob M Murray, Bodo Wiegand, Boris Hadaschik, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 22, 2021
2021: the year [<sup>177</sup>Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to "A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands" by Dr. Germo Gericke
Ken Herrmann, Clemens Kratochwil, Wolfgang P Fendler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 1, 2017
<sup>177</sup>Lu-PSMA Radioligand Therapy for Prostate Cancer
Wolfgang P Fendler, Kambiz Rahbar, Ken Herrmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
December 16, 2017
Comparison of <sup>68</sup>Ga-PSMA-11 and <sup>18</sup>F-Fluciclovine PET/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence
Jeremie Calais, Wolfgang P Fendler, Ken Herrmann, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 3, 2017
CXCR4 Ligands: The Next Big Hit?
Annemiek M E Walenkamp, Constantin Lapa, Ken Herrmann, et al.
Page
of 73